This Project Grant award, totaling $902,964.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to evaluate mechanisms that restrain or enhance alveolar macrophage (AM) responses to Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis, with the goal of understanding the regulation of early events during MTB infection. The key...
This Project Grant award of $176,152, provided by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify new drug targets against drug-tolerant strains of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The research aims to study the role of lipid metabolism and host-pathogen interactions in conferring drug tolerance to MTB strains with deficient glycerol...
This Project Grant award of $461,250 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Yale University to understand antibiotic tolerance in Mycobacterium tuberculosis (MTB). The key objectives are to: 1) Identify the subcellular environments and carbon sources associated with drug-tolerant MTB, and 2) Develop in vitro culture conditions mimicking these environments for future...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,817,044 in funding to the University of Massachusetts Medical School (UMass Medical) to conduct research on the systems genetics of tuberculosis. The grant supports a multifaceted research program that aims to understand the complex biological determinants of tuberculosis infection outcomes, leveraging...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $404,108 to the University of California, Davis (UC Davis) to identify genetic and signaling pathways that enable Mycobacterium tuberculosis (MTB) persister cells to survive antibiotic treatment. The award aims to apply genetic and proteomic approaches to uncover the core mechanisms driving MTB...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $140,256 to Washington University to conduct research on how the tuberculosis (TB) pathogen Mycobacterium tuberculosis (MTB) promotes its survival in neutrophils. The key objectives are to: 1) Investigate how the MTB type VII secretion system (T7SS), specifically the ESX-1 component, affects neutrophil phagosome...
This Project Grant award of $2,248,740.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is funding research by Michigan State University to develop new nitro-containing compounds to treat mycobacterial infections, including tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections. The key products and services to be delivered include: Optimizing a series of novel nitrofuran compounds, such as the parent...
This Project Grant award of $774,881, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855), supports research to develop pro-apoptotic small molecule host-directed therapies (HDTs) for the treatment of pulmonary tuberculosis (TB). The research aims to utilize these novel HDTs to shorten TB treatment duration, enhance antibiotic penetration, and prevent post-TB lung disease. The project leverages...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $294,824 to the University of Massachusetts Medical School (UMass Medical) to investigate strategies for enhancing the efficacy of antibiotics against Mycobacterium tuberculosis (MTB) infections. The key objectives are to understand the mechanistic link between glutamine starvation, immune pressure vulnerability, and reduced antibiotic tolerance in MTB. The research plan involves using MTB strains deficient in glutamine synthesis or host glutamine import to induce glutamine starvation and assess its impact on antibiotic efficacy during murine and intracellular infection models. The project aims to pave the way for new therapeutic approaches that directly target MTB viability and disrupt antibiotic tolerance, leading to more effective tuberculosis treatment regimens. The award period runs from October 1, 2024 to April 30, 2027.